Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy Volunteers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* BMI between 18 and 29.9 kg/m², inclusive~* Females must be of non-childbearing potential; If of child-bearing potential, must have negative pregnancy test and confirm the use of one of the appropriate means of contraception~* Males must agree to use appropriate methods of barrier contraception or have documented surgical sterilization~Exclusion Criteria:~* Diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the GI tract~* Any surgery on the small intestine or colon, excluding appendectomy~* Loose stools (Bristol Stool Form Score of 6 or 7) ≥2 days in the past 7 days~* Hepatic dysfunction (\[ALT\] or \[AST\]) \>1.5 times the upper limit of normal or renal impairment~* Any evidence of or treatment of malignancy, excluding non-melanomatous malignancies of the skin~* Use of diuretic medications, medications that are known to affect stool consistency and/or GI motility~* Use of an investigational agent within 30 days prior to Day -2~* Positive virology, alcohol, or drugs of abuse test during screening~* Use of any prescription medication within 7 days before admission to the CPU~* Have had significant blood loss (\>450 mL) or have donated 1 or more units of blood or plasma within 8 weeks prior to study entry

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- RDX5791 10mg QD (SAD phase) (Type: EXPERIMENTAL): 10mg of RDX5791 administered once daily PO fasting
- RDX5791 50mg QD (SAD phase) (Type: EXPERIMENTAL): 50mg of RDX5791 administered once daily PO fasting
- RDX5791 150mg QD (SAD phase) (Type: EXPERIMENTAL): 150mg of RDX5791 administered once daily PO fasting
- RDX5791 450mg QD (SAD phase) (Type: EXPERIMENTAL): 450mg of RDX5791 administered once daily PO fasting
- RDX5791 900mg QD (SAD phase) (Type: EXPERIMENTAL): 900mg of RDX5791 administered once daily PO fasting
- RDX5791 3mg QD (MAD phase) (Type: EXPERIMENTAL): 3mg of RDX5791 administered once daily PO fasting
- RDX5791 10mg QD (MAD phase) (Type: EXPERIMENTAL): 10mg of RDX5791 administered once daily PO fasting
- RDX5791 30 mg QD (MAD phase) (Type: EXPERIMENTAL): 30mg of RDX5791 administered once daily PO fasting
- RDX5791 100 mg QD (MAD phase) (Type: EXPERIMENTAL): 100mg of RDX5791 administered once daily PO fasting

Based on this trial design, predict the completion outcome and termination type (if applicable).